Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LRRC15-antiTGFβR2
- Development stage
- Preclinical
- Lead developer
- Bonum Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Systemic
01
Overview
LRRC15-antiTGFβR2 is an investigational monoclonal antibody being developed by Bonum Therapeutics for the treatment of cancer. It is designed as a conditionally active therapeutic that targets both leucine-rich repeat-containing protein 15 (LRRC15) and transforming growth factor-beta receptor type 2 (TGFβR2). The antibody remains inactive in systemic circulation to prevent the toxicities associated with broad TGF-β inhibition. Upon reaching the tumor microenvironment, it binds to LRRC15, which is highly expressed on suppressive cancer-associated fibroblasts (CAFs). This binding triggers the activation of the anti-TGFβR2 component, allowing for localized inhibition of TGF-β signaling. This targeted approach aims to remodel the immunosuppressive stroma and enhance anti-tumor immune responses while minimizing systemic side effects.
- Other names
- LRRC15-dependent anti-TGFβR2 antibody
02
Targets
TGFBR2 (TGF-β receptor type 2)LRRC15 (Leucine-rich repeat-containing protein 15)
Beyond the preview
Go deeper on LRRC15-antiTGFβR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LRRC15-antiTGFβR2.